Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation

NCT02979821 is registered in ClinicalTrials.gov with Korean Association for the Study of Targeted Therapy as lead sponsor.

NCT NCT02979821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02979821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation
Lead sponsor
Korean Association for the Study of Targeted Therapy
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
December 31, 2017
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma lung stage iv, her2 gene mutation